May 15, 2018

The pharmaceutical research company Roots Analysis talks to CEO Brian Frenzel about Tosk’s promising kRAS program.

Roots Analysis: We are aware that Tosk is focused on the development of discovery stage drug candidates targeting KRAS mutations. Can you provide some insights on […]
March 20, 2018

California Drug Developer Tosk, Inc. Announces Two Milestones for Transformational Cancer Treatment

Tosk, Inc., marks six months of significant human trials of drug eliminating toxic effects of common cancer therapies, grant by National Cancer Institute (NCI). MOUNTAIN VIEW, […]
February 6, 2018

Tosk has been awarded a $2 million grant from National Cancer Institute to continue the company’s TK-kRAS research program.

The National Cancer Institute (NCI) has awarded Tosk a two-year, $2 million grant to continue its highly promising oncologic kRAS research program. The kRAS project is […]
December 12, 2017

Preclinical efficiency testing in a rat model of doxorubicin-induced cardiotoxicity reduction has demonstrated statistically significant protection.

TK-39, Tosk’s second patented product, which blocks damage to the heart (cardiotoxicity) resulting from widely used cancer drugs known as anthracyclines, has proved preclinical efficacy testing […]
December 1, 2017

Tosk has had excellent though preliminary results of its recently inaugurated human trials for its TK-90 drug, which protects against mucositis.

Tosk has initiated human trials for its TK-90 drug, and preliminary results are encouraging. The drug is intended to reduce or eliminate the side effects of […]
July 15, 2017

Tosk Reports Initiation of POC Human Studies

MOUNTAIN VIEW, Calif.–(EON: Enhanced Online News)–Tosk, Inc. reported today the completion of Phase 1 safety trials and the initiation of POC studies in human cancer patients […]